Barclays’s Intersect ENT, Inc XENT Stock Holding History

Barclays’s Portfolio XENT Stock Details XENT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-12,000	Closed	-$299K	–	6622
2019 Q4	$299K	Sell	12,000 -83,000	-87%	-$1.68M	﹤0.01%	4734
2019 Q3	$1.62M	Buy	+95,000	New	+$1.73M	﹤0.01%	3122
2018 Q4	–	Sell	-9,100	Closed	-$262K	–	7529
2018 Q3	$262K	Sell	9,100 -5,900	-39%	-$177K	﹤0.01%	4786
2018 Q2	$562K	Buy	+15,000	New	+$589K	﹤0.01%	3834

Barclays's XENT Position: Q2 2022 in Review

Barclays sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 355,531 shares — an estimated $9.96M sold.

Barclays first reported a position in XENT in Q4 2014 and held it in 30 quarters. The position peaked at $12.5M in Q4 2019. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.

Barclays reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
Barclays sold 355,531 Intersect ENT, Inc shares in Q2 2022, an estimated $9.96M.
Barclays first reported a position in Intersect ENT, Inc in Q4 2014 and held it in 30 quarters.
Barclays's Intersect ENT, Inc position peaked at $12.5M in Q4 2019.
0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.

Based on Barclays's 13F filing for Q2 2022, filed 12 Aug 2022.